Name: Lyme / PTLDS research tracker data, 2026
Creator: Open Source Medicine Foundation
License: https://creativecommons.org/licenses/by/4.0/

Research Tracker
Annual Reports
Lyme / PTLDS: state of the evidence 2026

Contents:

Summary
Literature
Clinical trials
Agents
Biomarkers
Cohorts
Methods
Limitations
Download the data
Cite

Summary

39studies dated 2026 in the feed

1registered trials matched

1trials recruiting or active

0trials started in 2026

36biomarkers catalogued

1research cohorts indexed

Read this first. The literature feed is a rolling window of the 75 most recent PubMed results for this condition (currently spanning 1 January 2025 to 5 July 2026), not a complete census of 2026 publications. Monthly counts before the window opens are zero for that reason, not because nothing was published. Only 1 trials match this condition; percentages would be misleading at this size, so counts are shown. Trials for this condition are identified by keyword match on the registry title and condition field, because the tracker's curated condition mapping does not yet cover it. Expect both misses and false positives. The literature feed was last refreshed on 8 July 2026; figures are as of that snapshot.

Literature indexed in 2026

The Lyme / PTLDS feed holds 39 PubMed records with a 2026 publication date (39 unique PMIDs) out of 75 records in the feed, drawn from 31 distinct journals. This is a moderate sample.

Records by publication month, 2026. Grey month labels are in the future. Months before the feed window opened are zero by construction.

Top journals

Journals with the most 2026 records in the feed (top 10; ties broken by first appearance).

Browse the live feed: Lyme / PTLDS research tracker. Weekly changes are in the research digest.

Clinical trials

1 of the 629 ClinicalTrials.gov records in the tracker snapshot (taken 2026-10-07) match Lyme / PTLDS (1 via keyword match). 1 are recruiting, not yet recruiting, enrolling by invitation or active; 0 list a 2026 start date and 1 had their registry record updated in 2026. Median planned or actual enrollment is 120 participants (1 trials report a figure).

By status

Overall status as recorded on ClinicalTrials.gov at snapshot.

By phase

"Not applicable" covers behavioural, device, rehabilitation and observational designs.

By sponsor type

Lead-sponsor class from the registry; "Academic / other" is the registry's OTHER category.

Agents under investigation

Interventions named in the most matched trials (top 1 of 1 distinct agents). A trial testing several agents counts once per agent.

Agent	Trials	Of which active
Lumbrokinase	1	1

All tracked trials: clinical trials tracker.

Therapeutic agents catalogue

The OSMF therapeutic-agents catalogue lists 4 agents with Lyme as a primary condition (of 605 agents overall). Evidence level is the catalogue's own coarse grading, assigned automatically from the number and type of linked studies and trials; it is not a GRADE assessment.

Catalogue evidence grading: anecdotal, preliminary or moderate. No agent for any condition is graded higher than moderate.

Browse: therapeutics atlas and agents.

Biomarkers catalogued

The Lyme / PTLDS biomarker atlas (last edited 2026-06-29) holds 36 marker entries across 7 categories, citing 5 distinct DOIs: 23 reported elevated, 2 reduced and 11 with mixed or inconsistent findings. Direction is relative to the comparison group in the cited source (usually healthy controls) and a single entry can rest on one study.

Elevated Reduced Mixed / inconsistent Not stated

Marker entries by atlas category, split by reported direction of change.

Category	Elevated	Reduced	Mixed	Total
Serologic	9	0	0	9
CSF	4	0	2	6
Inflammatory	4	0	2	6
Molecular	1	0	3	4
Co-infection	4	0	0	4
Chronic/PTLDS	0	1	3	4
Functional	1	1	1	3

Full atlas: Lyme / PTLDS biomarker atlas.

Research cohorts

1 of the 32 cohorts in the OSMF post-acute infection syndrome (PAIS) cohort database relate to Lyme / PTLDS, together enrolling about 234 participants where a figure is recorded. This is a curated database, not a systematic census of cohorts.

Cohort	Design	Enrolled	Biobank	Registration
Johns Hopkins SLICE early-Lyme cohort (Aucott/Rebman)	prospective inception	234	active	—

Methods

This page was generated by scripts/build_reports.py on 7 October 2026 from the data snapshot described below. No number is entered by hand.

Studies. Records in data/lyme.json (source: PubMed (NCBI); feed last updated 2026-07-08) whose pub_date parses to a date in 2026. Year-only or year-month dates are mapped to the first day of the period. 0 record(s) had no parseable date and were excluded. Monthly counts bin by publication month; journal counts use the record's journal string verbatim (no normalisation of abbreviations).
Trials. Records in data/clinical_trials/clinical_trials_current.json (snapshot 2026-10-07). A trial matches when its mapped_conditions contains no curated label (none defined), or when its title or raw condition list matches the pattern(s) /\blyme\b/i, /borreli/i, /\bptlds\b/i. Status, phase and sponsor type are the registry's own fields, counted once per trial. "Started in 2026" uses start_date; "updated in 2026" uses last_updated. Agents are the tracker's normalised intervention names; a trial with several agents counts once for each. Median enrollment uses the registry enrollment field (actual or estimated) where numeric.
Agents catalogue. Entries in data/therapeutic_agents.json (updated 2026-10-07) whose "Primary Conditions" includes 'Lyme', grouped by the catalogue's "Evidence Level" string.
Biomarkers. Entries in data/biomarkers/lyme.json, grouped by category and direction (up, down, mixed). Distinct DOIs count unique reference.doi values.
Cohorts. Entries in data/pais-cohorts-index.json (version 2.0.0-seed) whose pathogen_id is in ['borrelia-burgdorferi'].

Limitations

The literature feed is a bounded, rolling PubMed query result. It captures recent indexing activity, not the full year, and PubMed indexing dates lag print publication. Counts here will not match a systematic search.
Study counts measure volume, not quality. No screening for study design, sample size, peer-review status or relevance beyond the search query was applied.
Trial matching depends on the tracker's condition mapping and keyword patterns; trials registered under umbrella terms (for example "post-viral fatigue") may be missed, and registry status fields are frequently stale.
Biomarker direction reflects what each cited source reported, often from a single cohort; "elevated" in one study does not imply replication.
The cohort database and agents catalogue are curated and incomplete, and the evidence-level grading is automatic and coarse.
Different sections rest on different snapshot dates (feed 2026-07-08, trials 2026-10-07, biomarkers 2026-06-29, agents 2026-10-07).
This is a year-to-date report; it is regenerated daily and will change until 31 December 2026.

Download the data

All inputs are public JSON files in the research-tracker repository, licensed for reuse with attribution.

Lyme / PTLDS literature feed (/data/lyme.json)
Clinical trials snapshot (all conditions) (/data/clinical_trials/clinical_trials_current.json)
Lyme / PTLDS biomarker atlas (/data/biomarkers/lyme.json)
Therapeutic agents catalogue (/data/therapeutic_agents.json)
PAIS cohort database index (/data/pais-cohorts-index.json)
The computed numbers behind this report (/reports/data/lyme-2026.json)

Suggested citation

Open Source Medicine Foundation. Lyme / PTLDS: state of the evidence 2026 (year-to-date, generated 7 October 2026). Open Source Medicine Foundation; 2026. https://research.opensourcemed.info/reports/lyme-state-of-the-evidence-2026.html

For a stable reference, cite the generation date shown; the page is regenerated as data arrive. Weekly updates: subscribe on Substack or follow the digest RSS feed.

Disclaimer. This report is an automated description of a research database maintained by the Open Source Medicine Foundation. It is not a systematic review and not medical advice. Discuss any treatment decision with a qualified clinician.